Premium
Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs
Author(s) -
Tomlin J. L.,
Sturgeon C.,
Pead M. J.,
Muir P.
Publication year - 2000
Publication title -
veterinary record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 99
eISSN - 2042-7670
pISSN - 0042-4900
DOI - 10.1136/vr.147.5.129
Subject(s) - medicine , osteosarcoma , osteolysis , bisphosphonate , tibia , bone density conservation agents , palliative care , surgery , maxilla , dentistry , pathology , osteoporosis , bone density , nursing
The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla. A spiral fracture associated with the tibial tumour healed after it was stabilised with an external skeletal fixator. Both dogs remained comfortable and survived for 12 and 10 months respectively after diagnosis, despite the fact that neither primary tumour was resected.